Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 12/20 | 0.72 |
| ▸ | NR1H4 | Q96RI1 | 7/20 | 0.72 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.56 |
| ▸ | SLC10A2 | Q12908 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.56 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.56 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL343908 | 0.88 | GPBAR1 (0.58) | GPBAR1NR1H4 | |
| SCHEMBL13811560 | 0.88 | GPBAR1 (0.77) | GPBAR1NR1H4MEN1KMT2AABCB11 | |
| SCHEMBL23710531 | 0.88 | NR1H4 (0.77) | GPBAR1NR1H4MEN1KMT2AABCB11 | |
| SCHEMBL17303269 | 0.88 | GPBAR1 (0.77) | GPBAR1NR1H4MEN1KMT2AABCB11 | |
| SCHEMBL15984655 | 0.88 | GPBAR1 (0.77) | GPBAR1NR1H4MEN1KMT2AABCB11 | |
| SCHEMBL1733816 | 0.87 | GPBAR1 (0.70) | GPBAR1NR1H4MEN1KMT2AABCB11 | |
| SCHEMBL21123905 | 0.87 | GPBAR1 (0.63) | GPBAR1NR1H4MEN1KMT2AABCB11 | |
| SCHEMBL17269248 | 0.86 | NR1H4 (0.65) | GPBAR1NR1H4MEN1KMT2AABCB11 | |
| SCHEMBL19957991 | 0.86 | NR1H4 (0.65) | GPBAR1NR1H4MEN1KMT2AABCB11 | |
| SCHEMBL11383608 | 0.86 | GPBAR1 (0.74) | GPBAR1NR1H4MEN1KMT2AABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114467578-B | Prevention and control method for plant nematodes | 海南大学 | 2023-06-06 | — | — | CN | disclosed |
| US-20190185572-A1 | COMBINATION THERAPY OF ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF | HOFFMANN-LA ROCHE INC. (US) | 2019-06-20 | — | — | US | disclosed |
| EP-3330292-A1 | HUMAN C-FMS ANTIGEN BINDING PROTEINS | Amgen, Inc (US) | 2018-06-06 | — | — | EP | disclosed |
| US-9988457-B2 | Human C-FMS antigen binding proteins | AMGEN INC. (US) | 2018-06-05 | — | — | US | disclosed |
| EP-2188313-B1 | HUMAN C-FMS ANTIGEN BINDING PROTEINS | AMGEN INC (US) | 2017-11-01 | — | — | EP | disclosed |
| US-20170247459-A1 | COMBINATION THERAPY OF ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF | HOFFMANN-LA ROCHE INC. (US) | 2017-08-31 | — | — | US | disclosed |
| US-20160340434-A1 | HUMAN C-FMS ANTIGEN BINDING PROTEINS | AMGEN INC. (US) | 2016-11-24 | — | — | US | disclosed |
| US-9303084-B2 | Human C-FMS antibodies | AMGEN INC. (US) | 2016-04-05 | — | — | US | disclosed |
| EP-1922337-B1 | TRAIL RECEPTOR 2 POLYPEPTIDES AND ANTIBODIES | AMGEN INC (US) | 2015-05-06 | — | — | EP | disclosed |
| EP-2822588-A1 | COMBINATION THERAPY OF ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2015-01-14 | — | — | EP | disclosed |
| EP-1773817-A1 | SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE | Amgen Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2007027713-A2 | TRAIL RECEPTOR 2 POLYPEPTIDES AND ANTIBODIES | AMGEN INC. (US) | 2007-03-08 | — | — | WO | disclosed |
| WO-2006107854-A2 | EPIDERMAL GROWTH FACTOR RECEPTOR GENE COPY NUMBER | AMGEN INC. (US) | 2006-10-12 | — | — | WO | disclosed |
| WO-2006045049-A1 | ANGIOPOIETIN-2 SPECIFIC BINDING AGENTS | AMGEN INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| EP-1648998-A2 | SPECIFIC BINDING AGENTS TO HEPATOCYTE GROWTH FACTOR | Amgen Inc. (US) | 2006-04-26 | — | — | EP | disclosed |
| US-20060040966-A1 | e.g. 2-(7-isoquinolinylamino)-N-(3-methyl-4-(1-methylethyl)phenyl)-3-pyridinecarboxamide; Vascular Endothelial Growth Factor antagonist; angiogenesis inhibitor; anticarcinogenic, antiinflammatory inhibitor; retinopathies, rheumatoid arthritis, asthma, atherosclerosis, endometriosis, neoplastic diseases | AMGEN INC. | 2006-02-23 | — | — | US | disclosed |
| WO-2006012374-A1 | SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20060018909-A1 | Angiopoietin-2 specific binding agents | AMGEN INC. | 2006-01-26 | — | — | US | disclosed |
| US-20050118643-A1 | Specific binding agents to hepatocyte growth factor | AMGEN INC | 2005-06-02 | — | — | US | disclosed |
| WO-2005017107-A2 | SPECIFIC BINDING AGENTS TO HEPATOCYTE GROWTH FACTOR | AMGEN INC. (US) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040966-A1 | e.g. 2-(7-isoquinolinylamino)-N-(3-methyl-4-(1-methylethyl)phenyl)-3-pyridinecarboxamide; Vascular Endothelial Growth Factor antagonist; angiogenesis inhibitor; anticarcinogenic, antiinflammatory inhibitor; retinopathies, rheumatoid arthritis, asthma, atherosclerosis, endometriosis, neoplastic diseases | EDNRA, PTGIS, EDNRB | GPBAR1 188/4885NR1H4 800/4885MEN1 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.